Ramaswamy Govindan
Washington University in St. Louis
551 Papers
2.9K Citations
Ramaswamy Govindan is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 85, co-authored 499 publications. Previous affiliations of Ramaswamy Govindan include University of North Carolina at Chapel Hill & Medical University of South Carolina.
Chat about Author
Papers
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Haeseong Park,Kerry J. Williams,Nikolaos A. Trikalinos,Sarah Larson,Benjamin R. Tan,Saiama N. Waqar,Rama Suresh,Daniel Morgensztern,Brian A. Van Tine,Ramaswamy Govindan,Jingqin Luo,A. Craig Lockhart,A. Craig Lockhart,Andrea Wang-Gillam +13 more
TL;DR: The combination of temsirolimus and erlotinib at the RP2D was well tolerated, and the regimen resulted in prolonged disease stabilization in selected patients (NCT00770263).
12
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Keunchil Park,Joshua K. Sabari,Eric B. Haura,Catherine A. Shu,Alexander I. Spira,Ravi Salgia,Karen L. Reckamp,Rachel E. Sanborn,Ramaswamy Govindan,Joshua Bauml,Joshua C. Curtin,John Xie,Amy K. Roshak,Patricia Lorenzini,Dawn Millington,Meena Thayu,Roland Elmar Knoblauch,Byoung Chul Cho +17 more
TL;DR: In this article , the authors reviewed infusion-related reaction (IRR) and subsequent management in amivantamab-treated patients and found that IRR was predominantly low grade and limited to first infusion, and rarely occurred with subsequent dosing.
12
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
Lawrence H. Einhorn,Philip Bonomi,Paul A. Bunn,D. Ross Camidge,David P. Carbone,Hak Choy,Hak Choy,Steven M. Dubinett,David R. Gandara,Laurie E. Gaspar,Ramaswamy Govindan,David H. Johnson,John D. Minna,Giorgio V. Scagliotti,Howard Jack West,Roy S. Herbst +15 more
TL;DR: In February 2007, a 3-day conference in Santa Monica was sponsored by the International Association for the Study of Lung Cancer, which brought together 50 world experts in the treatment of this disease.
12
Molecularly targeted therapies in locally advanced non-small-cell lung cancer.
TL;DR: The outline of a proposed prospective clinical trial to evaluate targeted drugs in molecularly selected group of patients with locally advanced NSCLC is presented.
12
3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)
Fabrice Barlesi,A-M.C. Dingemans,I. Ou,Jin Seok Ahn,Luigi De Petris,Dong Wook Kim,James Chih-Hsin Yang,Brett G.M. Hughes,Hervé Lena,Denis Moro-Sibilot,Alessandra Bearz,Santiago Viteri,T. Mekhail,Alexander I. Spira,Ali Zeaiter,Walter Bordogna,C. Sturm,Sophie Golding,Peter N. Morcos,Ramaswamy Govindan +19 more
12